Bergan Kdv Wealth Management, LLC Phathom Pharmaceuticals, Inc. Put Options Transaction History
Bergan Kdv Wealth Management, LLC
- $999 Million
- Q2 2023
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$104 Million5.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.5 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$35.8 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.4 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.1 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $402M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...